# A medicinal cannabis pioneer | eKathimerini.com > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/a-medicinal-cannabis-pioneer-ekathimerini-com/ > **Published:** 2026-07-07T17:15:24-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:58:38-04:00 > **Clinical Summary:** Clinical perspective on regulated cannabis medicine manufacturing in Europe and what standardization means for patient care and clinician access. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. IndustryResearchPainAnxietyCBDPolicySafety Clinical Summary # Clinical Summary This article highlights Anthera, a Greek family business emerging as a key player in the growing medicinal [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/), reflecting the broader expansion of cannabis-based pharmaceutical development across Europe and globally. As regulatory frameworks continue to evolve and clinical acceptance of [cannabis therapeutics](https://cedclinic.com/firearms-regulatory-guidance-cannabis/) increases, companies like Anthera are positioned to contribute to standardized product development and [supply chain](https://cedclinic.com/michigan-cannabis-industry-consolidation-license-decline/) infrastructure that could improve medication consistency and availability for patients. The growth of established, regulated manufacturers in traditionally non-cannabis markets signals a shift toward pharmaceutical-grade production standards that may enhance product safety and therapeutic reliability compared to unregulated sources. For clinicians, the emergence of legitimate pharmaceutical producers in regulated markets offers potential pathways to prescribe [evidence-based cannabis](https://cedclinic.com/jama-cannabis-review-physician-analysis/) products with known [cannabinoid profiles](https://cedclinic.com/cannabis-clinical-trials-mental-health-march-2026/) and quality assurance, rather than directing patients toward variable or unregulated alternatives. Clinicians should monitor developments in their own regulatory jurisdictions to understand which manufactured cannabis products may eventually become available for therapeutic use and what prescribing frameworks might apply. Clinical Perspective πŸ’Š The emergence of medicinal cannabis as a legitimate therapeutic option requires clinicians to move beyond stigma while maintaining appropriate skepticism about early industry claims. As commercial entities like Anthera expand production and market access in regions such as Greece, healthcare providers should recognize that industry growth does not necessarily reflect robust clinical evidence for most cannabis applications. The current evidence base remains limited and fragmented across conditions, with dosing, formulations, and long-term safety profiles still poorly characterized compared to conventional pharmaceuticals. Clinicians should stay informed about evolving regulatory frameworks and access pathways in their jurisdictions while critically appraising any cannabis products their patients inquire about, focusing on the specific condition, available evidence quality, and whether established alternatives exist. A practical approach involves engaging patients who are interested in cannabis with evidence-based conversations rather than categorical dismissals, while documenting reasoning and maintaining heightened vigilance for drug interactions and adverse effects given cannabis’s variable composition and individual variability πŸ’¬ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan β†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion β†’](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20A%20medicinal%20cannabis%20pioneer%20%7C%20eKathimerini.com%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68544)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68544)[πŸ¦… Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20A%20medicinal%20cannabis%20pioneer%20%7C%20eKathimerini.com%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68544)[πŸ“· Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[πŸ“ Read more on Substack](https://doctorapprovedcannabis.substack.com/)[πŸ”” Subscribe via RSS](https://cedclinic.com/feed/) πŸ“° Source: [https://www.ekathimerini.com/economy/1308791/a-medicinal-cannabis-pioneer/](https://www.ekathimerini.com/economy/1308791/a-medicinal-cannabis-pioneer/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).